- Celldex Therapeutics Inc Presentation of Barzolvolimab Phase 2 Results in Chronic Spontaneous Urticaria at AAAAI 2024 TranscriptFeb 25, 2024
- Celldex Therapeutics Inc Conference Call & Webcast TranscriptNov 06, 2023
- Celldex Therapeutics Inc at Cantor Fitzgerald Global Healthcare Conference TranscriptSep 26, 2023
- Celldex Therapeutics Inc at Jefferies Healthcare Conference TranscriptJun 07, 2023
- Celldex Therapeutics Inc at HC Wainwright Autoimmune & Inflammatory Disease Virtual Conference (Virtual) TranscriptMar 30, 2023
- Celldex Therapeutics Inc Presentation of Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria TranscriptFeb 26, 2023
- Celldex Therapeutics Inc Barzolvolimab Global Urticaria Forum 2022 Data Presentations and Program Update Call TranscriptDec 06, 2022
- Celldex Therapeutics Inc Corporate Call - Barzolvolimab Interim Phase 1b Multiple Ascending Dose Chronic Spontaneous Urticaria Study Results EAACI 2022 TranscriptJun 30, 2022
- Q4 2021 Celldex Therapeutics Inc Earnings Call TranscriptFeb 28, 2022$29.9 (-0.83%)Earnings
- Celldex Therapeutics Inc at SVB Leerink Global Healthcare (Virtual) TranscriptFeb 16, 2022
- Celldex Therapeutics Inc to Discuss the CDX-0159 Phase 1b Study Results in Cold Urticaria and Symptomatic Dermographism Late Breaking Presentation at EAACI 2021 - Conference Call TranscriptJul 12, 2021
- Celldex Therapeutics Inc - Phase 1b CIndU Interim Data Update TranscriptMar 29, 2021
- Q2 2020 Celldex Therapeutics Inc Earnings Call TranscriptAug 06, 2020$11.71 (+1.39%)Earnings
- Celldex Therapeutics Inc Annual Shareholders Meeting TranscriptJun 18, 2020
- Q2 2019 Celldex Therapeutics Inc Earnings Call TranscriptAug 07, 2019$2.16 (+3.85%)Earnings
- Q4 2018 Celldex Therapeutics Inc Earnings Call TranscriptMar 07, 2019$4.6 (-1.71%)Earnings
Celldex Therapeutics Inc at HC Wainwright Autoimmune & Inflammatory Disease Virtual Conference (Virtual) Transcript
Okay. Welcome back, everybody, to H.C. Wainwright's Autoimmune and Inflammatory Disease Virtual Conference, with a focus on skin disorders and diseases. My name is Joe Pantginis. I'm the director of research and managing director here at the firm. Very happy to have our next fireside chat, Celldex Therapeutics, which I've been covering for quite some time.
I'll make that comment later too, but really happy that we can have this discussion today. With us is Anthony Marucci, the Founder and CEO of the company; Tibor Keler, another Founder, Executive Vice President, and Chief Scientific Officer of the company, and Dr. Diane Young, Senior Vice President and Chief Medical Officer at the company.
So with that said, I'm looking forward to dive right in here, because there's a lot of data to talk about, a lot of ins and outs of what's been going on at the company. But the Celldex story has been quite visible over the last year, primarily due to Barzolvolimab, formerly CDX-0159. And as I've been saying, I've been covering the story for many
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)